L.E.A.F. Pharmaceuticals currently has several new products in development, targeting solid tumors.  Investigational New Drug (IND) enabling Good Laboratory Practice (GLP) toxicology studies are currently underway for lead products, LEAF-1401 and LEAF-1701.